

MHC-I and MHC-II epitope Peptides

fon:

+49 (0)731 - 3608 123 fax:+49 (0)731 - 3608 962

eMail:

info@genaxxon.com

www.genaxxon.com

MHC-I restricted peptide epitopes

MHC-I glycoproteins are designed for the recognition of infected cells and tumor cells.

T cell epitopes are presented on the surface of antigenpresenting cells by MHC molecules. T cell epitopes presented by MHC class I molecules are typically peptides between 8 and 11 amino acids in length and exhibiting MHC-specific sequence motifs.

These antigenic peptides are derived from non-structural and structural proteins through proteolysis in the cytosolic compartment. Peptide-MHC-I complexes are then transported to the cell surface of antigen presenting cells and are recognised by CD8+ cytotoxic T lymphocytes (CTL). This interaction induces the differentiation of CTLs. Activated CTL lyse the infected cell, secrete cytokines, and proliferate.

This mechanism ensures that cells infected by viruses or intracellular bacteria or cancer cells can be detected, since pathogen or cancer-specific MHC peptide complexes are displayed on the cell surface. CTL can recognise such abnormal cells and eliminate them.

The genes of MHC I and II molecules are polymorphic. Each MHC allele has a distinct peptide binding motif which favours certain amino acid anchor residues at defined sequence positions.

References:

R. Vita, L. Zarebski, J. A. Greenbaum, H. Emami, I. Hoof, N. Salimi, R. Damle, A. Sette, B. Peters (2010) Nucleic Acids Res. Jan. 38 D854-62. Epub 2009 Nov. 11 (www.immuneepitope.org).

H.-G. Rammensee, J. Bachmann, N.N. Emmerich, O.A. Bachor, S. Stevanović (1999) Immunogenetics 50, 213-219 (www.syfpeithi.de).

H.-G. Rammensee, T. Friede, S. Stevanović (1995) Immunogenetics 41, 178-228.

K. Falk, O. Rötzschke, S. Stevanović, G. Jung, H.-G. Rammensee (1991) Nature 351, 290 - 296. doi:10.1038/351290a0.

Ova (257-264): SIINFEKL			
SIINFEKL			
	Purity		
P2275	≥70%	5mg	
P2318	≥95%	5mg	

Influenza A NP (366-374)		
ASNENMETM		
	Purity	
P2276	≥70%	5mg
P2319	≥95%	5mg

Influenza A matrix protein (58-66)			
GILGFVFTL			
	Purity		
P2277	≥70%		5mg
P2320	≥95%	1mg	5mg

HIV-1 p17 Gag (77-85)			
SLYNTVATL			
	Purity		
P2278	≥70%		5mg
P2321	≥95%	1mg	5mg

HCV-NS5b			
ALYDVVS L			
	Purity		
P2279	≥70%		5mg
P2322	≥95%	1mg	5mg



LCMV GP (33-41)			
KAVYNFATM			
	Purity		
P2280	≥70%		5mg
P2323	≥95%	1mg	5mg

Melan-A / MART-1 (27 - 35)				
AAGIGILT	AAGIGILTV			
	Purity			
P2281	≥70%		5mg	
P2324	≥95%	1mg	5mg	

MAGE-3 antigen (271-279)			
FLWGPRALV			
	Purity		
P2282	≥70%		5mg
P2325	≥95%	1mg	5mg

MHC-II restricted peptide epitopes

MHC-II class molecules are designed for the recognition of epitopes of exogenous antigens and for discriminating self from non-self. They are expressed on the surface of antigen presenting cells.

The peptide binding groove of MHC II molecules is open at both ends, thus allowing MHC II-bound peptides to extend beyond both termini. Therefore MHC II epitopes are usually longer than MHC I epitopes and exhibit considerable length variation of 11-25 amino acids.

MHC class II molecules activate CD4+ helper T lymphocytes, which modulate humoral (B cell) and cell-mediated (CTL) immune response.

Activation of helper T lymphocytes lead to cell proliferation and secretion of cytokines which activate effector cells and trigger B cell proliferation and their differentiation into antibody-secreting plasma cells.

The genes of MHC-I and II molecules are polymorphic. Each MHC allele has a distinct peptide binding motif which favours certain amino acid anchor residues at defined sequence positions. Several promiscuous peptides, capable of binding to many different MHC class II alleles, have been identified.

References:

R. Vita, L. Zarebski, J. A. Greenbaum, H. Emami, I. Hoof, N. Salimi, R. Damle, A. Sette, B. Peters (2010) Nucleic Acids Res. Jan. 38 D854-62. Epub 2009 Nov. 11 (www.immuneepitope.org).

H.-G. Rammensee, J. Bachmann, N. N. Emmerich, O. A. Bachor, S. Stevanović (1999) Immun. 50, 213-219 (www.syfpeithi.de).

Ova (323-339)				
ISQAVHAAHAEINEAGR				
	Purity			
P2283	≥70%		5mg	
P2326	≥95%	1mg	5mg	

PADRE				
AKFVAAWTLKAAA				
	Purity			
P2284	≥70%		5mg	
P2327	≥95%	1mg	5mg	

Version: 110314



General terms and conditions

The following terms and conditions shall exclusively apply to all sales and shall be an integral part of each single agreement concluded between the parties. Verbal agreements are only valid if confirmed in writing. By placing an order the Buyer acknowledges our terms and conditions. Other conditions require our previous consent in writing.

Offers and orders

Our offers are subject to change without prior notice with respect to price, quantity, delivery time and availability. The Buyer's orders shall become binding for Genaxxon upon receipt by the Buyers of Genaxxon's written order acknowledgment (or invoice or delivery note).

Statements and any details in advertising materials shall not constitute any kind of warranty.

Any information, statements or representations, written or oral, by Genaxxon's employees, agents or representatives are not binding unless confirmed in writing on our business paper signed by a duly authorized officer. Genaxxon reserves the right to insist on a written order and/or references from the Buyer before proceeding the order. There is no minimum order value.

Prices

All prices of this price list are net prices in Euro (EUR / €) except if otherwise indicated. Our prices are exclusive of VAT. Goods are charged with the prices valid on the date of delivery. Payment in other currency requires a written quotation in the foreign currency.

Any tax, duty or charge imposed by governmental authority or otherwise and any other applicable taxes, duties or charges shall be charged to the Buyer's account.

Freight and packing charges will be added, they can be invoiced as a lump-sum charge.

Delivery / transfer of perils

Unless otherwise agreed by the Buyer and GENAXXON, the price shall be for delivery ex factory, packing excluded.

From the time of delivery the goods shall be at the risk of the Buyer. We are not liable for damage or loss during transportation. Except when explicitly specified by the Buyer we will decide on the appropriate type of transportation. If the type of transportation is specified, the Buyer has to bear any additional costs. The same shall apply in the case of raised transportation costs, additional expenses incurred by deviation, storage, tec. unless freight free delivery was explicitly agreed upon, after signing the agreement but before delivery.

Date of delivery / force majeure

GENAXXON intends to ship the goods within 7 working days from receipt of order, if possible otherwise within 28 days. There shall be no fixed period of delivery. Notwithstanding the preceding paragraph, if a fixed period for delivery has been agreed upon, and should GENAXXON default with the supply, the Buyer shall grant GENAXXON a reasonable respite, normally four weeks. If GENAXXON is unable to meet Buyers written delivery conditions, or a 28 day delivery, GENAXXON will inform the Buyer at the earliest opportunity. Delivery shall be subject to punctual delivery of the appropriate goods by GENAXXON's own suppliers. The day of delivery shall be the day on which the goods leave GENAXXON's plant or, if that day cannot be ascertained, the day on which the goods are put at the Buyer's disposal.

Force Majeure and unforeseeable hindrances of any kind beyond the control of GENAXXON (e.g. shortage of raw materials and supplies, Force Majeure) shall relieve the party from its obligation to supply as long as and to the extent that the hindrance prevails.

If unforeseeable hindrances of any kind beyond the control of GENAXXON occur (e.g. shortage of raw materials, force majeure) delivery period shall be extended as long as and to the extent that the hindrance prevails.

If delivery is delayed due to the above reasons the Buyer cannot claim any rights.

Terms of payment

Terms for customers with an open account are 14 days from invoice date unless otherwise agreed in writing. Other terms of payment require our previous written consent. For unpaid invoices 20 days beyond maturity we will charge interest on arrears amounting to the usual bank rate, at least 7% per annum exceeding the base rate of the European Central Bank. Delayed payment or irregular payments entitle us to discontinue delivery to the Buyer without any compensation. Instead of the agreed terms of payment we can ask for advance payment or security deposit, should doubts as to the solvency of a Buyer arise. In case of liquidation of the Buyer's company, or if GENAXXON learns about an oath of manifestation or a change of ownership due to financial difficulties we reserve the right to withdraw from the contract. We reserve the right to use incoming payments for liquidation of the oldest debts, in sequence as follows: costs, interests and then debt claims. Prepayments and advance payments must be paid plus VAT.

Government/Corporate Visa, MasterCard and JCB credit card may be accepted on approved accounts for payment of the Products. Payment by credit card will only be taken when ordered by fax or mail.

Intellectual property rights / patents

No warranty or representation is given by GENAXXON that the Products do not infringe any letters patent, trademarks, registered designs or other industrial rights. The Buyer is liable for his infringements of copyrights and industrial or intellectual properties, especially patents and trademarks

If products are custom-made to specification, the Buyer assumes the responsibility that the manufacture of these products does not infringe any patents or rights of a third party. The Buyer is liable for all damages and claims resulting from such infringement and hold the seller free and harmless from all claims.

The Buyer further warrants to GENAXXON that any use of the Products in the United States of America shall not result in the Products becoming adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act (or such equivalent legislation in force in the Buyer's jurisdiction) and shall not be materials which may not, under sections 404, 505 or 512 of the Act, be introduced into interstate commerce.

Version: 110314



Retention of title

Title of the goods shall not pass to the Buyer until he has fulfilled all liabilities arising from his business connection with GENAXXON, which shall include settling accessory claims and claims for damages and honouring cheques and bills. In the event of non-payment, we shall have the right to re-sell the goods to a third party. GENAXXON shall have the absolute authority to retake, sell or otherwise deal with or dispose of all or any part of the goods in which title remains vested in the seller. Until such time as the property in the goods passes to the Buyer, the Buyer shall hold the goods as the seller's fiduciary agent, and shall keep the goods properly stored, protected, and insured on his own costs.

Damages

No claims for compensation may be lodged by the Buyer including those of a non-contractual nature – for any minor negligent breach of duty by GENAXXON, his executive staff or other agents, unless such breach concerns damages resulting from death, injury or damage to health. However, this shall not affect the applicability of compelling statutory liability regulations.

Notifications of defects

All goods have to be checked immediately on receipt. Damage claims are only acceptable in writing within 8 working days of receipt of all the goods. In case of legitimate claims the Buyer can only require replacement of the goods. If replacement is not possible, the Buyer has the right to choose between alternative products with same value or refund. The Buyer cannot claim further compensation. All returns must first be authorized by us in writing.

Technical support, use and processing, properties of goods

Technical advice provided by GENAXXON verbally, in writing or by way of trials is given in good faith but without warranty, and this shall also apply where proprietary rights of third parties are involved. GENAXXON's technical advice shall not release the Buyer from the obligation to test the products supplied by GENAXXON as to their suitability for the intended processes and uses. The application, use and processing of the products are beyond GENAXXON's control and therefore entirely in the Buyer's responsibility.

Attention should be paid to the enclosed product descriptions, warnings and instruction leaflets.

Any arbitrary modification of the documents (e.g. instruction leaflets) and/or modification of the product is at your own risk.

Safety

At the Buyer's firm, all chemicals must be handled only by competent, suitably trained persons, familiar with laboratory procedures and potential chemical hazards. The burden of safe use of the Products of GENAXXON vests in the Buyer. The Buyer assumes all responsibility for warning his employees, and any person who might reasonably be expected to come into contact with the Products, of all risks to person and property in any way connected with the Products and for instructing them in their safe handling and use. The Buyer also assumes the responsibility for the safe disposal of all products in accordance with all applicable laws.

Product quality, specifications and technical information

Products are analysed in the laboratories of GENAXXON by methods and procedures which GENAXXON considers appropriate. In the event of any dispute concerning reported discrepancies arising from the Buyer's analytical results, determined by the Buyer's own analytical procedures, GENAXXON reserves the right to rely on the results of own analytical methods of GENAXXON. Certificates of Analysis or Certificates of Conformity are available at the discretion of GENAXXON for bulk orders but not normally for pre-pack orders. GENAXXON reserves the right to make a charge for such Certification.

Specifications may change and reasonable variation from any value listed should not form the basis of a dispute. Any supply by GENAXXON of bespoke or custom Product for a Buyer shall be to a specification agreed by both parties in writing.

Technical information provided orally, in writing, or by electronic means by or on behalf of GENAXXON, including any descriptions, references, illustrations or diagrams in any Catalogue or brochure, is provided for guidance purposes only and is subject to change.

Uses, warranties and liabilities

All products of GENAXXON bioscience GmbH are not for any commercial use or resale. They are intended solely for laboratory research and development purposes and are not to be used for any other purpose. GENAXXON bioscience GmbH offers no warranty regarding the fitness of any Product for a particular purpose and shall not be responsible for any loss or damage whatsoever arising there from.

The Buyer acknowledges that, since the products of GENAXXON are intended for research purposes, they may not be on the Toxic Substances Control Act 1976 ("TSCA") inventory. The Buyer warrants that it shall ensure that the Products are approved for use under the TSCA (or such other equivalent legislation in force in the Buyer's jurisdiction), if applicable. The Buyer shall be responsible for complying with any legislation or regulations governing the use of the Products and their import into the country of destination (for the avoidance of doubt to include, without limitation, the TSCA and all its amendments, all EINECS, ELINCS and NONS regulations).

If any licence or consent of any government or other authority shall be required for the acquisition, carriage or use of the products by the Buyer the Buyer shall obtain the same at its own expense and if necessary produce evidence of the same to GENAXXON on demand. Failure to do so shall not entitle the Buyer to withhold or delay payment. Any additional expenses or charges incurred by GENAXXON resulting from such failure shall be for the Buyer's account.

Workings and syntheses are undertaken with all due care and attention. In case(s) of claims involving negligence, liability for such claims shall be limited to the total amount paid in respect of the invoice. In particular, liability cannot be accepted for results obtained with the product(s) or for loss of profits.

Applicable law and jurisdiction / miscellaneous clauses

All contracts are subject to the laws of the Federal Republic of Germany. In the case of a legal dispute the jurisdiction of the court in Ulm (Germany) will be decisive and have exclusive jurisdiction. GENAXXON shall have the right to bring a claim before a court at the Buyer's principal place of business or at his discretion before any other court being competent according to any national or international law.

Version: 110314



Application of the Uniform Law on the International Sale of Goods and the Uniform Law on the Formation of Contracts for the International Sale of Goods and of the UN agreement on the sale of goods shall be excluded. Customary clauses shall be interpreted in accordance with the applicable Incoterms.

Even if it has been agreed that GENAXXON pays the customs and import duties of the destination country, any increase in such duties which becomes effective between the date of the order acknowledgement and delivery of the goods shall be borne by the Buyer. All other charges, taxes and costs connected with the purchase contract shall also be borne by the Buyer.

In the event that any provision of these Terms and Conditions is invalid or becomes invalid, the remainder of the Terms and Conditions shall remain unaffected thereby. The invalid provision shall then be replaced by such provision as comes as close as possible to the economic purpose of such invalid provision, taking reasonable account of the interests of both Parties.